These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 26883271)

  • 1. ABCG2 and ABCB1 Limit the Efficacy of Dasatinib in a PDGF-B-Driven Brainstem Glioma Model.
    Mittapalli RK; Chung AH; Parrish KE; Crabtree D; Halvorson KG; Hu G; Elmquist WF; Becher OJ
    Mol Cancer Ther; 2016 May; 15(5):819-29. PubMed ID: 26883271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment.
    Lagas JS; van Waterschoot RA; van Tilburg VA; Hillebrand MJ; Lankheet N; Rosing H; Beijnen JH; Schinkel AH
    Clin Cancer Res; 2009 Apr; 15(7):2344-51. PubMed ID: 19276246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Active efflux of Dasatinib from the brain limits efficacy against murine glioblastoma: broad implications for the clinical use of molecularly targeted agents.
    Agarwal S; Mittapalli RK; Zellmer DM; Gallardo JL; Donelson R; Seiler C; Decker SA; Santacruz KS; Pokorny JL; Sarkaria JN; Elmquist WF; Ohlfest JR
    Mol Cancer Ther; 2012 Oct; 11(10):2183-92. PubMed ID: 22891038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osimertinib (AZD9291) Enhanced the Efficacy of Chemotherapeutic Agents in ABCB1- and ABCG2-Overexpressing Cells In Vitro, In Vivo, and Ex Vivo.
    Chen Z; Chen Y; Xu M; Chen L; Zhang X; To KK; Zhao H; Wang F; Xia Z; Chen X; Fu L
    Mol Cancer Ther; 2016 Aug; 15(8):1845-58. PubMed ID: 27196753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategies to Inhibit ABCB1- and ABCG2-Mediated Efflux Transport of Erlotinib at the Blood-Brain Barrier: A PET Study on Nonhuman Primates.
    Tournier N; Goutal S; Auvity S; Traxl A; Mairinger S; Wanek T; Helal OB; Buvat I; Soussan M; Caillé F; Langer O
    J Nucl Med; 2017 Jan; 58(1):117-122. PubMed ID: 27493269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ATP-binding cassette transporter inhibitor potency and substrate drug affinity are critical determinants of successful drug delivery enhancement to the brain.
    Lentzas A; de Gooijer MC; Zuidema S; Meurs A; Çitirikkaya CH; Venekamp N; Beijnen JH; van Tellingen O
    Fluids Barriers CNS; 2024 Aug; 21(1):62. PubMed ID: 39103921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PI3K-mTOR Pathway Inhibition Exhibits Efficacy Against High-grade Glioma in Clinically Relevant Mouse Models.
    Lin F; de Gooijer MC; Hanekamp D; Chandrasekaran G; Buil LC; Thota N; Sparidans RW; Beijnen JH; Würdinger T; van Tellingen O
    Clin Cancer Res; 2017 Mar; 23(5):1286-1298. PubMed ID: 27553832
    [No Abstract]   [Full Text] [Related]  

  • 8. Molecular Imaging of ABCB1 and ABCG2 Inhibition at the Human Blood-Brain Barrier Using Elacridar and
    Verheijen RB; Yaqub M; Sawicki E; van Tellingen O; Lammertsma AA; Nuijen B; Schellens JHM; Beijnen JH; Huitema ADR; Hendrikse NH; Steeghs N
    J Nucl Med; 2018 Jun; 59(6):973-979. PubMed ID: 29175983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration.
    Tang SC; Lagas JS; Lankheet NA; Poller B; Hillebrand MJ; Rosing H; Beijnen JH; Schinkel AH
    Int J Cancer; 2012 Jan; 130(1):223-33. PubMed ID: 21351087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ABCB1, ABCG2, and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapy.
    Lin F; de Gooijer MC; Roig EM; Buil LC; Christner SM; Beumer JH; Würdinger T; Beijnen JH; van Tellingen O
    Clin Cancer Res; 2014 May; 20(10):2703-13. PubMed ID: 24647572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physical blood-brain barrier disruption induced by focused ultrasound does not overcome the transporter-mediated efflux of erlotinib.
    Goutal S; Gerstenmayer M; Auvity S; Caillé F; Mériaux S; Buvat I; Larrat B; Tournier N
    J Control Release; 2018 Dec; 292():210-220. PubMed ID: 30415015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of ABCB1 and ABCG2 at the Mouse Blood-Brain Barrier with Marketed Drugs To Improve Brain Delivery of the Model ABCB1/ABCG2 Substrate [
    Traxl A; Mairinger S; Filip T; Sauberer M; Stanek J; Poschner S; Jäger W; Zoufal V; Novarino G; Tournier N; Bauer M; Wanek T; Langer O
    Mol Pharm; 2019 Mar; 16(3):1282-1293. PubMed ID: 30694684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux.
    Agarwal S; Sane R; Gallardo JL; Ohlfest JR; Elmquist WF
    J Pharmacol Exp Ther; 2010 Jul; 334(1):147-55. PubMed ID: 20421331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PET-CT imaging with [(18)F]-gefitinib to measure Abcb1a/1b (P-gp) and Abcg2 (Bcrp1) mediated drug-drug interactions at the murine blood-brain barrier.
    Vlaming ML; Läppchen T; Jansen HT; Kivits S; van Driel A; van de Steeg E; van der Hoorn JW; Sio CF; Steinbach OC; DeGroot J
    Nucl Med Biol; 2015 Nov; 42(11):833-41. PubMed ID: 26264927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ABC Transporter Inhibition Plus Dexamethasone Enhances the Efficacy of Convection Enhanced Delivery in H3.3K27M Mutant Diffuse Intrinsic Pontine Glioma.
    Tsvankin V; Hashizume R; Katagi H; Herndon JE; Lascola C; Venkatraman TN; Picard D; Burrus B; Becher OJ; Thompson EM
    Neurosurgery; 2020 May; 86(5):742-751. PubMed ID: 31225627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P-glycoprotein Limits Ribociclib Brain Exposure and CYP3A4 Restricts Its Oral Bioavailability.
    Martínez-Chávez A; van Hoppe S; Rosing H; Lebre MC; Tibben M; Beijnen JH; Schinkel AH
    Mol Pharm; 2019 Sep; 16(9):3842-3852. PubMed ID: 31329454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.
    Tang SC; Nguyen LN; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
    Int J Cancer; 2014 Mar; 134(6):1484-94. PubMed ID: 24037730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of the coadministration of the p-glycoprotein modulator elacridar on the pharmacokinetics of lapatinib and its distribution in the brain and cerebrospinal fluid.
    Karbownik A; Sobańska K; Płotek W; Grabowski T; Klupczynska A; Plewa S; Grześkowiak E; Szałek E
    Invest New Drugs; 2020 Jun; 38(3):574-583. PubMed ID: 31177402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.
    Durmus S; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
    Mol Pharm; 2012 Nov; 9(11):3236-45. PubMed ID: 23020847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib.
    Dohse M; Scharenberg C; Shukla S; Robey RW; Volkmann T; Deeken JF; Brendel C; Ambudkar SV; Neubauer A; Bates SE
    Drug Metab Dispos; 2010 Aug; 38(8):1371-80. PubMed ID: 20423956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.